KD Logo

Agios Pharmaceuticals Inc (AGIO) rating initates by Scotiabank

Agios Pharmaceuticals Inc’s recent filing unveils that its Principal Accounting Officer Washburn Theodore James Jr. unloaded Company’s shares for reported $78134.0 on Feb 05 ’25. In the deal valued at $34.39 per share,2,272 shares were sold. As a result of this transaction, Washburn Theodore James Jr. now holds 5,437 shares worth roughly $ 0.18 million.

Then, Milanova Tsveta sold 2,804 shares, generating $90,233 in total proceeds. Upon selling the shares at $32.18, the Chief Commercial Officer now owns 18,906 shares.

Before that, Milanova Tsveta bought 2,804 shares. Agios Pharmaceuticals Inc shares valued at $89,279 were divested by the Officer at a price of $31.84 per share.

Scotiabank initiated its Agios Pharmaceuticals Inc [AGIO] rating to a Sector outperform in a research note published recently. Leerink Partners also remained covering AGIO and has decreased its forecast on September 27, 2024 with a “Market perform” recommendation from previously “an Outperform” rating. Cantor Fitzgerald started covering the stock on February 08, 2024. It rated AGIO as “an Overweight”.

Price Performance Review of AGIO

On Tuesday, Agios Pharmaceuticals Inc [NASDAQ:AGIO] saw its stock jump 1.17% to $33.61. Over the last five days, the stock has lost -1.06%. Agios Pharmaceuticals Inc shares have risen nearly 2.28% since the year began. Nevertheless, the stocks have risen 29.77% over the past one year. While a 52-week high of $62.58 was reached on 01/08/25, a 52-week low of $24.88 was recorded on 01/17/25. SMA at 50 days reached $36.76, while 200 days put it at $42.87.

Levels Of Support And Resistance For AGIO Stock

The 24-hour chart illustrates a support level at 32.91, which if violated will result in even more drops to 32.20. On the upside, there is a resistance level at 34.59. A further resistance level may holdings at 35.56. The Relative Strength Index (RSI) on the 14-day chart is 44.60, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 41.93%. Stochastics %K at 50.70% indicates the stock is a holding.

The most recent change occurred on February 03, 2023 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $41 price target.

Most Popular